Skip to main content
GutCited

Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome.

K Davis, S Philpott, D Kumar, M Mendall
RCT International journal of clinical practice 2006 50 citazioni
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D16749917'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo di studio
Randomized Controlled Trial
Dimensione del campione
58
Popolazione
IBS patients in secondary care
Durata
4 weeks
Intervento
Randomised double-blind placebo-controlled trial of aloe vera for irritable bowel syndrome. None
Comparatore
Matching placebo
Esito primario
Randomised double-blind placebo-controlled trial of aloe vera for irritable bowe
Direzione dell'effetto
Neutral
Rischio di bias
Moderate

Abstract

Aloe vera (AV) is suggested to be beneficial in treating irritable bowel syndrome (IBS) symptoms, but no scientific trials exist to confirm this. We aim to assess the efficacy of AV on IBS in refractory secondary care patients. Patients with IBS were randomised to receive AV or matching placebo for a month. Symptoms were assessed at baseline, 1 and 3 months. Fifty-eight patients randomised, 49 completed the protocol to 1 month and 41 to 3 months. Eleven of thirty-one (35%) AV patients, and 6 of 27 (22%) placebo patients responded at 1 month (p = 0.763). Diarrhoea predominant patients showed a trend towards a response to treatment at 1 month (10/23 V 2/14, p = 0.07). There was no evidence that AV benefits patients with IBS. However, we could not rule out the possibility that improvement occurred in patients with diarrhoea or alternating IBS whilst taking AV. Further investigations are warranted in patients with diarrhoea predominant IBS, in a less complex group of patients.

TL;DR

There was no evidence that AV benefits patients with IBS, however, it could not rule out the possibility that improvement occurred in patients with diarrhoea or alternating IBS whilst taking AV, in a less complex group of patients.

Used In Evidence Reviews

Similar Papers